Rapid Non-Invasive Brain Stimulation for Hoarding Disorder

Not Applicable

Not yet recruiting

• Conditions: Hoarding Disorder; Hoarding; Clutter

• Registration Number: NCT06712914
• Lead Sponsor: Stanford University

Brief Summary

This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.

Detailed Description

Hoarding disorder (HD) is characterized by difficulty letting go of possessions, leading to clutter that congests living spaces and impairs daily functioning. The majority of HD patients treated with cognitive behavioral therapy for HD usually experience considerable residual symptoms. New treatments are greatly needed. This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.

Study Timeline

• Study First Submitted: 2024-11-27
• Study First Submitted QC: 2024-11-27
• Study First Posted: 2024-12-02
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-14
• Last Update Posted: 2025-04-16
• Study Start: 2025-06-01
• Primary Completion: 2025-12-31
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Age 18-70 years
2. Primary diagnosis of hoarding disorder
3. Sufficient severity of hoarding symptoms
4. Willing and able to understand and complete consent and study procedures

Exclusion Criteria

1. Psychiatric or medical conditions or medications that make participation unsafe
2. Pregnant or nursing females
3. Previous exposure to TMS or ECT
4. History of any implanted device or psychosurgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Change in Compulsive Acquisition Scale (CAS)	Change from baseline to 3 weeks after treatment starts	The Compulsive Acquisition Scale (CAS) is an 18-item questionnaire that measures the extent to which individuals acquire and feel compelled to acquire possessions.; The total score (sum of 18 items) ranges from 0 to 126. Total score higher than 48 shows significant difficulty with acquiring.

Trial Locations

Locations (1)

Stanford University Medical Center; 🇺🇸 Palo Alto, California, United States